BIIB vs NWS Comparison

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

News Corporation is a diversified media conglomerate with significant presence in the us, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings business in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable us digital property advertising business, Move. An agreement has been reached to sell Foxtel, the Australian pay-TV and streaming provider in which News Corp has a 65% shareholding. The sale to global sports streaming platform, DAZN, is struck at more than 7 times Foxtel's fiscal 2024 EBITDA, equating to enterprise value of AUD 3.4.